REFERENCIAS

• Williams W y col. Hematology. McGraw Hill Book, New York, 1983.

• Wintrobe MM. Clinical Hematology. 8a. ed. Lea Febriger, Philadelphia, 1981.

• Sans Sabra ten J y col. Hematologia ch nica. Barcelona, Mosby, 1994.

• Tierney LM Jr, McPhee SJ, Papadakis M. Current Medical Diagnosis and Treatment. 34 De. Norwalk  Connecticut Appleton and Lange 1995. Charles A. Linker MD.

• Rossbanch HC, Grana NH, Chamizo W, Barrios NJ, Barbosa JL. Successful allogeneic bone marrow transplantation for agnogenic myeloid metaplasia in a 3 year old boy. Am J Hernatol 1995; 52 (2):144-146.

• Le Bousse Kerdiles MC y col. Differential expression of transforming growth factor beta, basic fibroblast growth factor, and their receptors in CD34 + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88 (12): 4534-4546.

• Tefferi A, Silverstein MN. Current perspective in agnogenic myeloid metaplasia. Leuk-Lymphoma 1996.22 (Supl. 1): 169-171.

• Sacchi S. The role of alpha interferon in essential thrombocythaemia, polyeythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leuk. Lymphoma 1995,19 (1-2):13-20.

• Levy V, Bougarit A, Delmer A, Legrand O, Baudard M, Rio B, Littoun R. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996; 53 (4): 239-241.

• Petroianu A. Subtotal splenectomy for treatment of patients with myelofibrosis and myeloid metaplasia. Int. Surg. 1996; 81 (2): 177-179.